4 results about "Prevention infection" patented technology

The present disclosure relates to compositions comprising lipid nanoparticles (LNPs) configured for targeting dendritic cells. In particular, the present disclosure provides LNPs comprising a serine-based helper-lipid, a PEG lipid, an ionizable lipid, a cholesterol component, and one or more nucleic acids. The present disclosure provides use of the LNPs for the delivery of nucleic acid molecules, specifically mRNA; thereby making them highly suitable for use in various therapeutics, such as for the treatment of cancer or autoimmune diseases or prevention of infectious diseases. Finally, methods are provided for preparing such LNPs.

Provided herein are pharmaceutical compositions that include a pharmaceutically active agent, a cellulose nanocrystal or a cellulose nanofiber, a thermogelling biocompatible polymer, and a gelling agent. Such pharmaceutical compositions can be configured as a bioink suitable for 3D printing. Such pharmaceutical compositions are suitable for treating bone disorders, including osteoporosis. Methods of treating Paget's disease, treating or preventing cancer, treating or preventing an infectious disease, and treating or preventing a disorder through regenerative medicine are also provided.

The present disclosure relates to an mRNA molecule encoding a polypeptide comprising an hMPV F protein, or an immunogenic fragment thereof, and a lumazine synthase (LuS) capable of multimerising to form a nanoparticle. Further aspects of the disclosure relate to compositions comprising the mRNA molecule and their use as a vaccine in the prevention of infectious diseases, including those caused by hMPV and RSV.

The present invention relates to a composition for use in the treatment or prevention of a respiratory infectious disease in a subject, wherein said composition comprises blood plasma and immunoglobulins directed against a causative agent of said respiratory infectious disease, wherein said immunoglobulins are obtained from a donor subject who has developed a humoral immune response to said causative agent of said respiratory infectious disease; and wherein said composition is administered intranasally, and optionally orally. The present invention further relates to a nasal, naso-oropharyngeal, or oro-nasal spray device comprising such composition and a nasal, naso-oropharyngeal, or oro-nasal spray comprising blood plasma and immunoglobulins directed against a causative agent of said respiratory infectious disease, wherein said immunoglobulins are obtained from a donor subject who has developed a humoral immune response to said causative agent of said respiratory infectious disease.